



PATENT

I hereby certify that on May 13, 2004, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Harry Lee

Applicant: Sung-Ho RYU et al.

Serial No.: 10/774,147

Filed: February 6, 2004

Title: **LEUKOCYTE STIMULATING
PEPTIDES**

Examiner: N/A

Art Unit: 1653

Attorney Docket No.: 10050-03USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached Form PTO/SB/08A (substitute for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Non-Patent Documents:

1. WU et al., Roles of phospholipid signaling in chemo attractant-induced responses, Journal of Cell Science, 2000; 113:2935-2940
2. SCHMITT et al., Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated *in vitro*, Nature immunology, 2004; 5:410-417

3. FAROOQUI et al., Phospholipase A2 and Its Role in Brain Tissue, *Journal of Neurochemistry*, 1997, 69:889-901
4. GIJON and LESLIE, Regulation of arachidonic acid release and cytosolic phospholipase A₂ activation, *Journal of Leukocyte Biology*, 1999; 65:330-336
5. GRYNKIEWICZ et al., A New Generation of Ca²⁺ Indicators with Greatly Improved Fluorescence Properties, *Journal of Biological Chemistry*, 1985; 260:3440-3450
6. HAYASHI et al., Synthetic Hexa- and Heptapeptides that inhibit IL-8 from Binding to and Activating Human Blood Neutrophils, *The Journal of Immunology*, 1995; 154:814-824
7. HE et al., The Synthetic Peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic Agonist for Mouse Formyl Peptide Receptor, *The Journal of Immunology*, 2000; 165:4598-4605
8. HIEMSTRA et al., Definition of Natural T Cell Antigens with Mimicry Epitopes Obtained from Dedicated Synthetic Peptide Libraries, *The Journal of Immunology*, 1998; 161:4078-4082
9. ITOH et al., Expression profile of Active Genes in Granulocytes, *Blood*, 1998; 4:1432-1441
10. LISCOVITCH et al., Phospholipase D: molecular and cell biology of a novel gene family, *Biochem. J.*, 2000; 345:401-415
11. M'RABET et al., Differential fMet-Leu-Phe- and Platelet-activating Factor-induced Signaling Toward Ral Activation in Primary Human Neutrophils, *Journal of Biological Chemistry*, 1999; 274:21847-21852
12. MURTHY and MAKHLOUF, Differential Regulation of Phospholipid A₂(PLA₂)-dependent. Ca²⁺ Signaling in smooth muscle by camp- and cGMP-dependent Protein Kinases, *Journal of Biological Chemistry*, 1998; 273:34519-34526

13. PAN et al., fMet-Leu-Phe Stimulates Proinflammatory Cytokine Gene Expression in Human Peripheral Blood Monocytes: The Role of Phosphatidylinositol 3-Kinase, *Journal of Immunology*, 2000; 164:404-411
14. PROSSNITZ et al., Signal Transducing Properties of the N-formyl Peptide Receptor Expressed in Undifferentiated HL60 Cells, *Journal of Immunology*, 1993; 151:5704-5715
15. PURI, Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms, *International Journal of Biochemistry and Cell Biology*, 1998; 30:1107-1122
16. RABIN et al., Chemokine Receptor Responses on T Cells are achieved through regulation of both receptor expression and signaling, *Journal of Immunology*, 1999; 162:3840-3850
17. ROBSON et al., Differential Regulation of Chemokine Production in Human Peritoneal Mesothelial Cells: IFN- γ Controls Neutrophil Migration Across the Mesothelium In Vitro and In Vivo, *Journal of Immunology*, 2001; 167:1028-1038
18. ARAMBURU et al., Affinity-Driven peptide selection of an NFAT Inhibitor More Selective than Cyclosporin A, *Science*, 1999; 285:2129-2133
19. BADOLATO et al., Serum Amyloid A Induces Calcium Mobilization and Chemotaxis of Human Monocytes by Activating a Pertussis Toxin-Sensitive Signaling Pathway, *Journal of Immunology*, 1995; 155:4004-4010
20. BAE et al., Identification of novel chemoattractant peptides for human leukocytes, *Blood*, 2001; 97:2854-2862
21. BAE et al., Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of *Staphylococcus aureus* via phospholipase D activation in human monocytes, *Journal of Leukocyte Biology*, 1999; 65:241-248


22. BAE et al., Independent Functioning of Cytosolic Phospholipase A2 Phospholipase D1 in Trp-Lys-Tyr-Met-Val-D-Met-Induced Superoxide Generation in Human Monocytes, Journal of Immunology, 2000; 164:4089-4096
23. BAEK et al., Identification of the Peptides that stimulate the Phosphoinositide Hydrolysis in Lymphocyte Cell Lines from Peptide Libraries, Journal of Biological Chemistry, 1996; 271:8170-8175
24. BERADI et al., Basic Fibroblast Growth Factor Mediates Its Effects on Committed Myeloid Progenitors by Direct Action and Has No Effect on Hematopoietic Stem Cells, Blood, 1995; 86:2123-2129
25. BOEN et al., Identification of T Cell Ligands in a Library of Peptides Covalently Attached to HLA-DR4, Journal of Immunology, 2000; 165:2040-2047
26. BRILL et al., Augmentation of RANTES-Induced Extracellular Signal-Regulated Kinase Mediated Signaling and T Cell Adhesion by Elastase-Treated Fibronectin, Journal of Immunology, 2001; 166:7121-7127
27. DANA et al., Essential Requirement of Cytosolic Phospholipase A2 for Activation of the Phagocyte NADPH Oxidase, Journal of Biological Chemistry, 1998; 273:441-445
28. DOOLEY et al., Selective Ligands for the μ , δ , and κ Opioid Receptors Identified from a Single Mixture Based Tetrapeptide Positional Scanning Combinatorial Library, Journal of Biological Chemistry, 1998; 273:18848-18856
29. ROBINSON et al., Activation of Phospholipase A2 in human neutrophils by polyunsaturated fatty acids and its role in stimulation of superoxide production, Biochem. J., 1998; 336:611-617
30. SANO et al., Human Galectin-3 is a Novel Chemoattractant for Monocytes and Macrophages, Journal of Immunology, 2000; 165:2156-2164
31. SEO et al., A Peptide with Unique Receptor Specificity, Journal of Immunology, 1997; 158:1895-1901

32. SUGDEN and CLERK, Regulation of the ERK Subgroup of MAP Kinase Cascades Through G Protein-Coupled Receptors, Cell. Signal, 9:337-351
33. WILSON et al., Immunogenicity. I. Use of Peptide Libraries to Identify Epitopes that activate clonotypic CD4+ T Cells and Induce T Cell Responses to Native Peptide Ligands, Journal of Immunology, 1999; 163:6424-6434
34. WOO et al., Leukotriene B4 Stimulates Rac-ERK Cascade to Generate Reactive Oxygen Species that Mediates Chemotaxis, Journal of Biological Chemistry, 2002; 277:8572-8578

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached Form PTO/SB/08A with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Respectfully submitted,

Dated May 13, 2004


Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425
Attorney for Applicants

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/774,147	
	Filing Date	02/05/2004	
	First Named Inventor	Sung-Ho RYU	
	Art Unit	1653	
	Examiner Name	N/A	
Total Number of Pages in This Submission	10 + Ref.	Attorney Docket Number	10050-03USA

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08B (4 pages); Copies of cited references C1 - C34; Return Receipt Postcard.
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Joseph Hyosuk Kim Reg. No. 41,425 JHK Law
Signature	
Date	May 13, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Harry Sung Lee		
Signature		Date	May 13, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/774,147
Filing Date	February 6, 2004
First Named Inventor	Sung-Ho RYU et al
Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	10050-03USA

Sheet 1 of 4

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	WU et al., Roles of phospholipid signaling in chemoattractant-induced responses, Journal of Cell Science, 2000; 113:2935-2940	
	C2	SCHMITT et al., Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro, Nature immunology, 2004; 5:410-417	
	C3	FAROOQUI et al., Phospholipase A2 and Its Role in Brain Tissue, Journal of Neurochemistry, 1997, 69:889-901	
	C4	GIJON and LESLIE, Regulation of arachidonic acid release and cytosolic phospholipase A2 activation, Journal of Leukocyte Biology, 1999; 65:330	
	C5	GRYNKIEWICZ et al., A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties, Journal of Biological Chemistry, 1985; 260:3440-3450	
	C6	HAYASHI et al., Synthetic Hexa- and Heptapeptides that inhibit IL-8 from Binding to and Activating Human Blood Neutrophils, The Journal of Immunology, 1995; 154:814-824	
	C7	HE et al., The Synthetic Peptide Trp-Lys-tyr-Met-Val-D-Met is a potent chemotactic Agonist for Mouse Formyl Peptide Receptor, The Journal of Immunology, 2000; 165:4598-4605	
	C8	HIEMSTRA et al., Definition of Natural T Cell Antigens with Mimicry Epitopes Obtained from Dedicated Synthetic Peptide Libraries, The Journal of Immunology, 1998; 161:4078-4082	
	C9	ITOH et. al., Expression profile of Active Genes in Granulocytes, Blood, 1998; 4:1432-1441	
	C10	LISCOVITCH et al., Phospholipase D: molecular and cell biology of a novel gene family, Biochem. J., 2000; 345:401-415	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/774,147
Filing Date	February 6, 2004
First Named Inventor	Sung-Ho RYU et al
Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	10050-03USA

Sheet 2 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	M'RABET et al., Differential fMet-Leu-Phe- and Plateletactivating Factor-induced Signaling Toward Ral Activation ---, Journal of Biological Chemistry, 1999; 274:21847-21852	
	C12	MURTHY and MAKHLOUF, Differential Regulation of Phospholipid A2(PLA2)-dependent. Ca2+ Signaling in smooth muscle ---, Journal of Biological Chemistry, 1998; 273:34519-34526	
	C13	PAN et al., fMet-Leu-Phe Stimulates Proinflammatory Cytokine Gene Expression in Human Peripheral Blood Monocytes: The Role of --, Journal of Immunology, 2000; 164:404-411	
	C14	PROSSNITZ et al., Signal Transducing Properties of the N-formyl Peptide Receptor Expressed in Undifferentiated HL60 Cells, Journal of Immunology, 1993; 151:5704-5715	
	C15	PURI, Phospholipase A2: its role in ADP- and thrombin-induced platelet actication mechanisms, International Journal of Biochemistry and Cell Biology, 1998; 30:1107-1122	
	C16	RABIN et al., Chemokine Receptor Responses on T Cells are achieved through regulation of both receptor expression and signaling, Journal of Immunology, 1999; 162:3840-3850	
	C17	ROBSON et al., Differential Regulation of Chemokine Production in Human Peritoneal Mesothelial Cells: IFN Controls Neutrophil ---, Journal of Immunology, 2001; 167:1028-1038	
	C18	ARAMBURU et al., Affinity-Driven peptide selection of an NFAT Inhibitor More Selective than Cyclosporin-A, Science., 1999; 285:2129-2133	
	C19	BADOLATO et al., Serum Amyloid A Induces Calcium Mobilization and Chemotaxis of Human Monocytes by Activating a Pertussic Toxin ---, Journal of Immunology, 1995; 155:4004-4010	
	C20	BAE et al., Identification of novel chemoattractant peptides for human leukocytes, Blood, 2001; 97:2854-2862	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/774,147
		Filing Date	February 6, 2004
		First Named Inventor	Sung-Ho RYU et al
		Art Unit	1653
		Examiner Name	N/A
Sheet 3	of 4	Attorney Docket Number	10050-03USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	BAE et al., Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus ---, Journal of Leukocyte Biology, 1999; 65:241-248	
	C22	BAE et al., Independent Functioning of Cytosolic Phospholipase A2 Phospholipase D1 in Trp-Lys-Tyr-Met-Val-D-Met-Induced ---, Journal of Immunology, 2000; 164:4089-4096	
	C23	BAEK et al., Identification of the Peptides that stimulate the Phosphoinositide Hydrolysis in Lymphocyte Cell Lines ---, Journal of Biological Chemistry, 1996; 271:8170-8175	
	C24	BERADI et al., Basic Fibroblast Growth Factor Mediates Its Effects on Committed Myeloid Progenitors by Direct Action and Has No Effect ---, Blood, 1995; 86:2123-2129	
	C25	BOEN et al., Identification of T Cell Ligands in a Library of Peptides Covalently Attached to HLA-DR4, Journal of Immunology, 2000; 165:2040-2047	
	C26	BRILL et al., Augmentation of RANTES-Induced Extracellular Signal-Regulated Kinase Mediated Signaling and T Cell Adhesion by ---, Journal of Immunology, 2001; 166:7121-7127	
	C27	DANA et al., Essential Requirement of Cytosolic Phospholipase A2 for Activation of the Phagocyte NADPH Oxidase, Journal of Biological Chemistry, 1998; 273:441-445	
	C28	DOOLEY et al., Selective Ligands for the --- Opioid Receptors Identified from a Single Mixture Based Tetrapeptide ---, Journal of Biological Chemistry, 1998; 273:18848-18856	
	C29	ROBINSON et al., Activation of Phospholipase A2 in human neutrophils by polyunsaturated fatty acids and its role in stimulation of ---, Biochem. J., 1998; 336:611-617	
	C30	SANO et al., Human Galectin-3 is a Novel Chemoattractant for Monocytes and Macrophages, Journal of Immunology, 2000; 165:2156-2164	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/774,147
Filing Date	February 6, 2004
First Named Inventor	Sung-Ho RYU et al
Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	10050-03USA

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C31	SEO et al., A Peptide with Unique Receptor Specificity, Journal of Immunology, 1997; 158:1895-1901	
	C32	SUGDEN and CLERK, Regulation of the ERK Subgroup of MAP Kinase Cascades Through G Protein-Coupled Receptors, Cell. Signal., 1997; 9:337-351	
	C33	WILSON et al., Immunogenicity.I. Use of Peptide Libraries to Identify Epitopes that activate clonotypic CD4+ T Cells and Induce ---, Journal of Immunology, 1999; 163:6424-6434	
	C34	WOO et al., Leukotriene B4 Stimulates Rac-ERK Cascade to Generate Reactive Oxygen Species that Mediates Chemotaxis, Journal of Biological Chemistry, 2002; 277:8572-8578	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.